WELLESLEY HILLS, Mass., Dec. 5 /PRNewswire-FirstCall/ -- MacroChem's (OTC Bulletin Board: MACM), (http://www.macrochem.com) President and CEO, Robert DeLuccia, will present at the upcoming Equities Magazine Winter Discovery Day Conference XV at the Princeton Club in New York City on December 7, 2007. Mr. DeLuccia is scheduled to present at 11:30 AM EST.
The Equities Corporate Conference is an all day event featuring special presentations from emerging public company CEOs from a wide range of sectors. The conference provides an opportunity for promising emerging growth companies to connect with the investment community. Interested parties can access a live audio webcast of the Company's presentation, through a link at http://www.equitiesmagazine.com. The presentation will be available for 90 days.
MacroChem Corporation is a specialty pharmaceutical company that develops and seeks to commercialize pharmaceutical products. Our lead product candidate is EcoNail, a topically applied SEPA-based econazole lacquer for the treatment of onychomycosis, a condition commonly known as nail fungus. We recently acquired exclusive worldwide license rights to pexiganan, a novel topical anti-infective for the treatment of diabetic foot infection, which has already completed two Phase 3 trials. Our other clinical stage product candidate, Opterone(R), is a topically applied SEPA-based testosterone cream designed to treat male hypogonadism. Our pipeline of clinical-stage and early-stage product candidates is based on our SEPA, MacroDerm(TM) and DermaPass(TM) drug delivery technologies. For more information visit our website, http://www.macrochem.com.
About Equities Magazine
EQUITIES magazine is focused on bringing together corporate executives
and corporate and instit
|SOURCE MacroChem Corporation|
Copyright©2007 PR Newswire.
All rights reserved